Xencor, Inc.
NOVEL CTLA4-IG IMMUNOADHESINS
Last updated:
Abstract:
The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes.
Status:
Application
Type:
Utility
Filling date:
15 Apr 2021
Issue date:
29 Jul 2021